Skip to main content
Top
Published in: Cancer and Metastasis Reviews 1/2008

01-03-2008

The Met tyrosine kinase receptor in development and cancer

Authors: Alessandra Gentile, Livio Trusolino, Paolo M. Comoglio

Published in: Cancer and Metastasis Reviews | Issue 1/2008

Login to get access

Abstract

Met is a tyrosine kinase receptor, encoded by an oncogene, whose crucial role has been elucidated during the last two decades. The complex biological program triggered by Met has been dissected and its biological relevance in both physiology and pathology has been proven. Met supports a morphogenetic program, known as invasive growth, taking place both during embryogenesis and adulthood. In tumors Met is often aberrantly activated, giving rise to the pathological counterpart of the invasive growth program: cancer progression towards metastasis. Several approaches have been recently developed to interfere with the tumorigenic and metastatic processes triggered by Met.
Literature
1.
go back to reference Cooper, C. S., Park, M., Blair, D. G., Tainsky, M. A., Huebner, K., Croce, C. M., et al. (1984). Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature, 311, 29–33.PubMedCrossRef Cooper, C. S., Park, M., Blair, D. G., Tainsky, M. A., Huebner, K., Croce, C. M., et al. (1984). Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature, 311, 29–33.PubMedCrossRef
2.
go back to reference Park, M., Testa, J. R., Blair, D. G., Parsa, N. Z., & Vande Woude, G. F. (1988). Two rearranged MET alleles in MNNG-HOS cells reveal the orientation of MET on chromosome 7 to other markers tightly linked to the cystic fibrosis locus. Proceedings of the National Academy of Sciences of the United States of America, 85, 2667–2671.PubMedCrossRef Park, M., Testa, J. R., Blair, D. G., Parsa, N. Z., & Vande Woude, G. F. (1988). Two rearranged MET alleles in MNNG-HOS cells reveal the orientation of MET on chromosome 7 to other markers tightly linked to the cystic fibrosis locus. Proceedings of the National Academy of Sciences of the United States of America, 85, 2667–2671.PubMedCrossRef
3.
go back to reference Park, M., Dean, M., Cooper, C. S., Schmidt, M., O’Brien, S. J., Blair, D. G., et al. (1986). Mechanism of met oncogene activation. Cell, 45, 895–904.PubMedCrossRef Park, M., Dean, M., Cooper, C. S., Schmidt, M., O’Brien, S. J., Blair, D. G., et al. (1986). Mechanism of met oncogene activation. Cell, 45, 895–904.PubMedCrossRef
4.
go back to reference Soman, N. R., Wogan, G. N., & Rhim, J. S. (1990). TPR-MET oncogenic rearrangement: Detection by polymerase chain reaction amplification of the transcript and expression in human tumor cell lines. Proceedings of the National Academy of Sciences of the United States of America, 87, 738–742.PubMedCrossRef Soman, N. R., Wogan, G. N., & Rhim, J. S. (1990). TPR-MET oncogenic rearrangement: Detection by polymerase chain reaction amplification of the transcript and expression in human tumor cell lines. Proceedings of the National Academy of Sciences of the United States of America, 87, 738–742.PubMedCrossRef
5.
go back to reference Giordano, S., Ponzetto, C., Di Renzo, M. F., Cooper, C. S., & Comoglio, P. M. (1989). Tyrosine kinase receptor indistinguishable from the c-met protein. Nature, 339, 155–156.PubMedCrossRef Giordano, S., Ponzetto, C., Di Renzo, M. F., Cooper, C. S., & Comoglio, P. M. (1989). Tyrosine kinase receptor indistinguishable from the c-met protein. Nature, 339, 155–156.PubMedCrossRef
6.
go back to reference Stoker, M., Gherardi, E., Perryman, M., & Gray, J. (1987). Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature, 327, 239–242.PubMedCrossRef Stoker, M., Gherardi, E., Perryman, M., & Gray, J. (1987). Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature, 327, 239–242.PubMedCrossRef
7.
go back to reference Nakamura, T., Nishizawa, T., Hagiya, M., Seki, T., Shimonishi, M., Sugimura, A., et al. (1989). Molecular cloning and expression of human hepatocyte growth factor. Nature, 342, 440–443.PubMedCrossRef Nakamura, T., Nishizawa, T., Hagiya, M., Seki, T., Shimonishi, M., Sugimura, A., et al. (1989). Molecular cloning and expression of human hepatocyte growth factor. Nature, 342, 440–443.PubMedCrossRef
8.
go back to reference Zarnegar, R., & Michalopoulos, G. (1989). Purification and biological characterization of human hepatopoietin A, a polypeptide growth factor for hepatocytes. Cancer Research, 49, 3314–3320.PubMed Zarnegar, R., & Michalopoulos, G. (1989). Purification and biological characterization of human hepatopoietin A, a polypeptide growth factor for hepatocytes. Cancer Research, 49, 3314–3320.PubMed
10.
go back to reference Weidner, K. M., Arakaki, N., Hartmann, G., Vandekerckhove, J., Weingart, S., Rieder, H., et al. (1991). Evidence for the identity of human scatter factor and human hepatocyte growth factor. Proceedings of the National Academy of Sciences of the United States of America, 88, 7001–7005.PubMedCrossRef Weidner, K. M., Arakaki, N., Hartmann, G., Vandekerckhove, J., Weingart, S., Rieder, H., et al. (1991). Evidence for the identity of human scatter factor and human hepatocyte growth factor. Proceedings of the National Academy of Sciences of the United States of America, 88, 7001–7005.PubMedCrossRef
11.
go back to reference Naldini, L., Vigna, E., Narsimhan, R. P., Gaudino, G., Zarnegar, R., Michalopoulos, G. K., et al. (1991). Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. Oncogene, 6, 501–504.PubMed Naldini, L., Vigna, E., Narsimhan, R. P., Gaudino, G., Zarnegar, R., Michalopoulos, G. K., et al. (1991). Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. Oncogene, 6, 501–504.PubMed
12.
go back to reference Bottaro, D. P., Rubin, J. S., Faletto, D. L., Chan, A. M., Kmiecik, T. E., Vande Woude, G. F., et al. (1991). Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science, 251, 802–804.PubMedCrossRef Bottaro, D. P., Rubin, J. S., Faletto, D. L., Chan, A. M., Kmiecik, T. E., Vande Woude, G. F., et al. (1991). Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science, 251, 802–804.PubMedCrossRef
13.
go back to reference Comoglio, P. M. (2002). Trusolino L: Invasive growth: From development to metastasis. Journal of Clinical Investigation, 109, 857–862.PubMedCrossRef Comoglio, P. M. (2002). Trusolino L: Invasive growth: From development to metastasis. Journal of Clinical Investigation, 109, 857–862.PubMedCrossRef
14.
go back to reference Montesano, R., Matsumoto, K., Nakamura, T., & Orci, L. (1991). Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. Cell, 67, 901–908.PubMedCrossRef Montesano, R., Matsumoto, K., Nakamura, T., & Orci, L. (1991). Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. Cell, 67, 901–908.PubMedCrossRef
15.
go back to reference Trusolino, L., & Comoglio, P. M. (2002). Scatter-factor and semaphorin receptors: Cell signalling for invasive growth. Nature Reviews Cancer, 2, 289–300.PubMedCrossRef Trusolino, L., & Comoglio, P. M. (2002). Scatter-factor and semaphorin receptors: Cell signalling for invasive growth. Nature Reviews Cancer, 2, 289–300.PubMedCrossRef
16.
go back to reference Maina, F., Casagranda, F., Audero, E., Simeone, A., Comoglio, P. M., Klein, R., et al. (1996). Uncoupling of Grb2 from the Met receptor in vivo reveals complex roles in muscle development. Cell, 87, 531–542.PubMedCrossRef Maina, F., Casagranda, F., Audero, E., Simeone, A., Comoglio, P. M., Klein, R., et al. (1996). Uncoupling of Grb2 from the Met receptor in vivo reveals complex roles in muscle development. Cell, 87, 531–542.PubMedCrossRef
17.
go back to reference Ponzetto, C., Bardelli, A., Zhen, Z., Maina, F., Dalla, Z. P., Giordano, S., et al. (1994). A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell, 77, 261–271.PubMedCrossRef Ponzetto, C., Bardelli, A., Zhen, Z., Maina, F., Dalla, Z. P., Giordano, S., et al. (1994). A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell, 77, 261–271.PubMedCrossRef
18.
go back to reference Zanetti, A., Stoppacciaro, A., Marzullo, A., Ciabatta, M., Fazioli, F., Prat, M., et al. (1998). Expression of Met protein and urokinase-type plasminogen activator receptor (uPA-R) in papillary carcinoma of the thyroid. Journal of Pathology, 186, 287–291.PubMedCrossRef Zanetti, A., Stoppacciaro, A., Marzullo, A., Ciabatta, M., Fazioli, F., Prat, M., et al. (1998). Expression of Met protein and urokinase-type plasminogen activator receptor (uPA-R) in papillary carcinoma of the thyroid. Journal of Pathology, 186, 287–291.PubMedCrossRef
19.
go back to reference Gaudino, G., Follenzi, A., Naldini, L., Collesi, C., Santoro, M., Gallo, K. A., et al. (1994). RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP. European Molecular Biology Organization Journal, 13, 3524–3532. Gaudino, G., Follenzi, A., Naldini, L., Collesi, C., Santoro, M., Gallo, K. A., et al. (1994). RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP. European Molecular Biology Organization Journal, 13, 3524–3532.
20.
go back to reference Huff, J. L., Jelinek, M. A., Borgman, C. A., Lansing, T. J., & Parsons, J. T. (1993). The protooncogene c-sea encodes a transmembrane protein-tyrosine kinase related to the Met/hepatocyte growth factor/scatter factor receptor. Proceedings of the National Academy of Sciences of the United States of America, 90, 6140–6144.PubMedCrossRef Huff, J. L., Jelinek, M. A., Borgman, C. A., Lansing, T. J., & Parsons, J. T. (1993). The protooncogene c-sea encodes a transmembrane protein-tyrosine kinase related to the Met/hepatocyte growth factor/scatter factor receptor. Proceedings of the National Academy of Sciences of the United States of America, 90, 6140–6144.PubMedCrossRef
21.
go back to reference Birchmeier, C., Birchmeier, W., Gherardi, E., & Vande Woude, G. F. (2003). Met, metastasis, motility and more. Nature Reviews. Molecular Cell Biology, 4, 915–925.PubMedCrossRef Birchmeier, C., Birchmeier, W., Gherardi, E., & Vande Woude, G. F. (2003). Met, metastasis, motility and more. Nature Reviews. Molecular Cell Biology, 4, 915–925.PubMedCrossRef
22.
go back to reference Gandino, L., Longati, P., Medico, E., Prat, M., & Comoglio, P. M. (1994). Phosphorylation of serine 985 negatively regulates the hepatocyte growth factor receptor kinase. Journal of Biological Chemistry, 269, 1815–1820.PubMed Gandino, L., Longati, P., Medico, E., Prat, M., & Comoglio, P. M. (1994). Phosphorylation of serine 985 negatively regulates the hepatocyte growth factor receptor kinase. Journal of Biological Chemistry, 269, 1815–1820.PubMed
23.
go back to reference Peschard, P., Fournier, T. M., Lamorte, L., Naujokas, M. A., Band, H., Langdon, W. Y., et al. (2001). Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Molecular Cell, 8, 995–1004.PubMedCrossRef Peschard, P., Fournier, T. M., Lamorte, L., Naujokas, M. A., Band, H., Langdon, W. Y., et al. (2001). Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Molecular Cell, 8, 995–1004.PubMedCrossRef
24.
go back to reference Furge, K. A., Zhang, Y. W., & Vande Woude, G. F. (2000). Met receptor tyrosine kinase: Enhanced signaling through adapter proteins. Oncogene, 19, 5582–5589.PubMedCrossRef Furge, K. A., Zhang, Y. W., & Vande Woude, G. F. (2000). Met receptor tyrosine kinase: Enhanced signaling through adapter proteins. Oncogene, 19, 5582–5589.PubMedCrossRef
25.
go back to reference Pelicci, G., Giordano, S., Zhen, Z., Salcini, A. E., Lanfrancone, L., Bardelli, A., et al. (1995). The motogenic and mitogenic responses to HGF are amplified by the Shc adaptor protein. Oncogene, 10, 1631–1638.PubMed Pelicci, G., Giordano, S., Zhen, Z., Salcini, A. E., Lanfrancone, L., Bardelli, A., et al. (1995). The motogenic and mitogenic responses to HGF are amplified by the Shc adaptor protein. Oncogene, 10, 1631–1638.PubMed
26.
go back to reference Weidner, K. M., Di, C. S., Sachs, M., Brinkmann, V., Behrens, J., & Birchmeier, W. (1996). Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis. Nature, 384, 173–176.PubMedCrossRef Weidner, K. M., Di, C. S., Sachs, M., Brinkmann, V., Behrens, J., & Birchmeier, W. (1996). Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis. Nature, 384, 173–176.PubMedCrossRef
27.
go back to reference Gual, P., Giordano, S., Anguissola, S., Parker, P. J., & Comoglio, P. M. (2001). Gab1 phosphorylation: A novel mechanism for negative regulation of HGF receptor signaling. Oncogene, 20, 156–166.PubMedCrossRef Gual, P., Giordano, S., Anguissola, S., Parker, P. J., & Comoglio, P. M. (2001). Gab1 phosphorylation: A novel mechanism for negative regulation of HGF receptor signaling. Oncogene, 20, 156–166.PubMedCrossRef
28.
go back to reference Gual, P., Giordano, S., Williams, T. A., Rocchi, S., Van, O. E., & Comoglio, P. M. (2000). Sustained recruitment of phospholipase C-gamma to Gab1 is required for HGF-induced branching tubulogenesis. Oncogene, 19, 1509–1518.PubMedCrossRef Gual, P., Giordano, S., Williams, T. A., Rocchi, S., Van, O. E., & Comoglio, P. M. (2000). Sustained recruitment of phospholipase C-gamma to Gab1 is required for HGF-induced branching tubulogenesis. Oncogene, 19, 1509–1518.PubMedCrossRef
29.
go back to reference Maroun, C. R., Naujokas, M. A., Holgado-Madruga, M., Wong, A. J., & Park, M. (2000). The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Molecular Cell Biology, 20, 8513–8525.CrossRef Maroun, C. R., Naujokas, M. A., Holgado-Madruga, M., Wong, A. J., & Park, M. (2000). The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Molecular Cell Biology, 20, 8513–8525.CrossRef
30.
go back to reference Fournier, T. M., Kamikura, D., Teng, K., & Park, M. (1996). Branching tubulogenesis but not scatter of Madin–Darby canine kidney cells requires a functional Grb2 binding site in the Met receptor tyrosine kinase. Journal of Biological Chemistry, 271, 22211–22217.PubMedCrossRef Fournier, T. M., Kamikura, D., Teng, K., & Park, M. (1996). Branching tubulogenesis but not scatter of Madin–Darby canine kidney cells requires a functional Grb2 binding site in the Met receptor tyrosine kinase. Journal of Biological Chemistry, 271, 22211–22217.PubMedCrossRef
31.
go back to reference O’brien, L. E., Tang, K., Kats, E. S., Schutz-Geschwender, A., Lipschutz, J. H., & Mostov, K. E. (2004). ERK and MMPs sequentially regulate distinct stages of epithelial tubule development. Developments in Cell, 7, 21–32.CrossRef O’brien, L. E., Tang, K., Kats, E. S., Schutz-Geschwender, A., Lipschutz, J. H., & Mostov, K. E. (2004). ERK and MMPs sequentially regulate distinct stages of epithelial tubule development. Developments in Cell, 7, 21–32.CrossRef
32.
go back to reference Marshall, C. J. (1995). Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation. Cell, 80, 179–185.PubMedCrossRef Marshall, C. J. (1995). Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation. Cell, 80, 179–185.PubMedCrossRef
33.
go back to reference Graziani, A., Gramaglia, D., Cantley, L. C., & Comoglio, P. M. (1991). The tyrosine-phosphorylated hepatocyte growth factor/scatter factor receptor associates with phosphatidylinositol 3-kinase. Journal of Biological Chemistry, 266, 22087–22090.PubMed Graziani, A., Gramaglia, D., Cantley, L. C., & Comoglio, P. M. (1991). The tyrosine-phosphorylated hepatocyte growth factor/scatter factor receptor associates with phosphatidylinositol 3-kinase. Journal of Biological Chemistry, 266, 22087–22090.PubMed
34.
go back to reference Ponzetto, C., Bardelli, A., Maina, F., Longati, P., Panayotou, G., Dhand, R., et al. (1993). A novel recognition motif for phosphatidylinositol 3-kinase binding mediates its association with the hepatocyte growth factor/scatter factor receptor. Molecular Cell Biology, 13, 4600–4608. Ponzetto, C., Bardelli, A., Maina, F., Longati, P., Panayotou, G., Dhand, R., et al. (1993). A novel recognition motif for phosphatidylinositol 3-kinase binding mediates its association with the hepatocyte growth factor/scatter factor receptor. Molecular Cell Biology, 13, 4600–4608.
35.
go back to reference Royal, I., & Park, M. (1995). Hepatocyte growth factor-induced scatter of Madin–Darby canine kidney cells requires phosphatidylinositol 3-kinase. Journal of Biological Chemistry, 270, 27780–27787.PubMedCrossRef Royal, I., & Park, M. (1995). Hepatocyte growth factor-induced scatter of Madin–Darby canine kidney cells requires phosphatidylinositol 3-kinase. Journal of Biological Chemistry, 270, 27780–27787.PubMedCrossRef
36.
go back to reference Trusolino, L., Cavassa, S., Angelini, P., Ando, M., Bertotti, A., Comoglio, P. M., et al. (2000). HGF/scatter factor selectively promotes cell invasion by increasing integrin avidity. FASEB Jounal, 14, 1629–1640.CrossRef Trusolino, L., Cavassa, S., Angelini, P., Ando, M., Bertotti, A., Comoglio, P. M., et al. (2000). HGF/scatter factor selectively promotes cell invasion by increasing integrin avidity. FASEB Jounal, 14, 1629–1640.CrossRef
37.
go back to reference Xiao, G. H., Jeffers, M., Bellacosa, A., Mitsuuchi, Y., Vande Woude, G. F., & Testa, J. R. (2001). Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proceedings of the National Academy of Sciences of the United States of America, 98, 247–252.PubMedCrossRef Xiao, G. H., Jeffers, M., Bellacosa, A., Mitsuuchi, Y., Vande Woude, G. F., & Testa, J. R. (2001). Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proceedings of the National Academy of Sciences of the United States of America, 98, 247–252.PubMedCrossRef
38.
go back to reference Wells, C. M., Abo, A., & Ridley, A. J. (2002). PAK4 is activated via PI3K in HGF-stimulated epithelial cells. Journal of Cell Science, 115, 3947–3956.PubMedCrossRef Wells, C. M., Abo, A., & Ridley, A. J. (2002). PAK4 is activated via PI3K in HGF-stimulated epithelial cells. Journal of Cell Science, 115, 3947–3956.PubMedCrossRef
39.
go back to reference Boccaccio, C., Ando, M., Tamagnone, L., Bardelli, A., Michieli, P., Battistini, C., et al. (1998). Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature, 391, 285–288.PubMedCrossRef Boccaccio, C., Ando, M., Tamagnone, L., Bardelli, A., Michieli, P., Battistini, C., et al. (1998). Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature, 391, 285–288.PubMedCrossRef
40.
go back to reference Corso, S., Comoglio, P. M., & Giordano, S. (2005). Cancer therapy: Can the challenge be MET. Trends in Molecular Medicine, 11, 284–292.PubMedCrossRef Corso, S., Comoglio, P. M., & Giordano, S. (2005). Cancer therapy: Can the challenge be MET. Trends in Molecular Medicine, 11, 284–292.PubMedCrossRef
41.
go back to reference Palka, H. L., Park, M., & Tonks, N. K. (2003). Hepatocyte growth factor receptor tyrosine kinase met is a substrate of the receptor protein-tyrosine phosphatase DEP-1. Journal of Biological Chemistry, 278, 5728–5735.PubMedCrossRef Palka, H. L., Park, M., & Tonks, N. K. (2003). Hepatocyte growth factor receptor tyrosine kinase met is a substrate of the receptor protein-tyrosine phosphatase DEP-1. Journal of Biological Chemistry, 278, 5728–5735.PubMedCrossRef
42.
go back to reference Sangwan, V., Paliouras, G. N., Cheng, A., Dube, N., Tremblay, M. L., & Park, M. (2006). Protein-tyrosine phosphatase 1B deficiency protects against Fas-induced hepatic failure. Journal of Biological Chemistry, 281, 221–228.PubMedCrossRef Sangwan, V., Paliouras, G. N., Cheng, A., Dube, N., Tremblay, M. L., & Park, M. (2006). Protein-tyrosine phosphatase 1B deficiency protects against Fas-induced hepatic failure. Journal of Biological Chemistry, 281, 221–228.PubMedCrossRef
43.
go back to reference Machide, M., Hashigasako, A., Matsumoto, K., & Nakamura, T. (2006). Contact inhibition of hepatocyte growth regulated by functional association of the c-Met/hepatocyte growth factor receptor and LAR protein-tyrosine phosphatase. Journal of Biological Chemistry, 281, 8765–8772.PubMedCrossRef Machide, M., Hashigasako, A., Matsumoto, K., & Nakamura, T. (2006). Contact inhibition of hepatocyte growth regulated by functional association of the c-Met/hepatocyte growth factor receptor and LAR protein-tyrosine phosphatase. Journal of Biological Chemistry, 281, 8765–8772.PubMedCrossRef
44.
go back to reference Birchmeier, C., & Gherardi, E. (1998). Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends in Cell Biology, 8, 404–410.PubMedCrossRef Birchmeier, C., & Gherardi, E. (1998). Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends in Cell Biology, 8, 404–410.PubMedCrossRef
45.
go back to reference Uehara, Y., Minowa, O., Mori, C., Shiota, K., Kuno, J., Noda, T., et al. (1995). Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature, 373, 702–705.PubMedCrossRef Uehara, Y., Minowa, O., Mori, C., Shiota, K., Kuno, J., Noda, T., et al. (1995). Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature, 373, 702–705.PubMedCrossRef
46.
go back to reference Bladt, F., Riethmacher, D., Isenmann, S., Aguzzi, A., & Birchmeier, C. (1995). Essential role for the c-Met receptor in the migration of myogenic precursor cells into the limb bud. Nature, 376, 768–771.PubMedCrossRef Bladt, F., Riethmacher, D., Isenmann, S., Aguzzi, A., & Birchmeier, C. (1995). Essential role for the c-Met receptor in the migration of myogenic precursor cells into the limb bud. Nature, 376, 768–771.PubMedCrossRef
47.
go back to reference Schmidt, C., Bladt, F., Goedecke, S., Brinkmann, V., Zschiesche, W., Sharpe, M., et al. (1995). Scatter factor/hepatocyte growth factor is essential for liver development. Nature, 373, 699–702.PubMedCrossRef Schmidt, C., Bladt, F., Goedecke, S., Brinkmann, V., Zschiesche, W., Sharpe, M., et al. (1995). Scatter factor/hepatocyte growth factor is essential for liver development. Nature, 373, 699–702.PubMedCrossRef
48.
go back to reference Maina, F., Pante, G., Helmbacher, F., Andres, R., Porthin, A., Davies, A. M., et al. (2001). Coupling Met to specific pathways results in distinct developmental outcomes. Molecular Cell, 7, 1293–1306.PubMedCrossRef Maina, F., Pante, G., Helmbacher, F., Andres, R., Porthin, A., Davies, A. M., et al. (2001). Coupling Met to specific pathways results in distinct developmental outcomes. Molecular Cell, 7, 1293–1306.PubMedCrossRef
49.
go back to reference Huh, C. G., Factor, V. M., Sanchez, A., Uchida, K., Conner, E. A., & Thorgeirsson, S. S. (2004). Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proceedings of the National Academy of Sciences of the United States of America, 101, 4477–4482.PubMedCrossRef Huh, C. G., Factor, V. M., Sanchez, A., Uchida, K., Conner, E. A., & Thorgeirsson, S. S. (2004). Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proceedings of the National Academy of Sciences of the United States of America, 101, 4477–4482.PubMedCrossRef
50.
go back to reference Chmielowiec, J., Borowiak, M., Morkel, M., Stradal, T., Munz, B., Werner, S., et al. (2007). c-Met is essential for wound healing in the skin. Journal of Cell Biology, 177, 151–162.PubMedCrossRef Chmielowiec, J., Borowiak, M., Morkel, M., Stradal, T., Munz, B., Werner, S., et al. (2007). c-Met is essential for wound healing in the skin. Journal of Cell Biology, 177, 151–162.PubMedCrossRef
51.
go back to reference Bussolino, F., Di Renzo, M. F., Ziche, M., Bocchietto, E., Olivero, M., Naldini, L., et al. (1992). Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. Journal of Cell Biology, 119, 629–641.PubMedCrossRef Bussolino, F., Di Renzo, M. F., Ziche, M., Bocchietto, E., Olivero, M., Naldini, L., et al. (1992). Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. Journal of Cell Biology, 119, 629–641.PubMedCrossRef
52.
go back to reference Boccaccio, C., Sabatino, G., Medico, E., Girolami, F., Follenzi, A., Reato, G., et al. (2005). The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature, 434, 396–400.PubMedCrossRef Boccaccio, C., Sabatino, G., Medico, E., Girolami, F., Follenzi, A., Reato, G., et al. (2005). The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature, 434, 396–400.PubMedCrossRef
53.
go back to reference Boccaccio, C., & Medico, E. (2006). Cancer and blood coagulation. Cellular and Molecular Life Sciences, 63, 1024–1027.PubMedCrossRef Boccaccio, C., & Medico, E. (2006). Cancer and blood coagulation. Cellular and Molecular Life Sciences, 63, 1024–1027.PubMedCrossRef
54.
go back to reference Rickles, F. R., & Levine, M. N. (2001). Epidemiology of thrombosis in cancer. Acta Haematologica, 106, 6–12.PubMedCrossRef Rickles, F. R., & Levine, M. N. (2001). Epidemiology of thrombosis in cancer. Acta Haematologica, 106, 6–12.PubMedCrossRef
55.
go back to reference Rong, S., Segal, S., Anver, M., Resau, J. H., & Vande Woude, G. F. (1994). Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation. Proceedings of the National Academy of Sciences of the United States of America, 91, 4731–4735.PubMedCrossRef Rong, S., Segal, S., Anver, M., Resau, J. H., & Vande Woude, G. F. (1994). Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation. Proceedings of the National Academy of Sciences of the United States of America, 91, 4731–4735.PubMedCrossRef
56.
go back to reference Taulli, R., Scuoppo, C., Bersani, F., Accornero, P., Forni, P. E., Miretti, S., et al. (2006). Validation of Met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. Cancer Research, 66, 4742–4749.PubMedCrossRef Taulli, R., Scuoppo, C., Bersani, F., Accornero, P., Forni, P. E., Miretti, S., et al. (2006). Validation of Met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. Cancer Research, 66, 4742–4749.PubMedCrossRef
57.
go back to reference Lutterbach, B., Zeng, Q., Davis, L. J., Hatch, H., Hang, G., Kohl, N. E., et al. (2007). Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Research, 67, 2081–2088.PubMedCrossRef Lutterbach, B., Zeng, Q., Davis, L. J., Hatch, H., Hang, G., Kohl, N. E., et al. (2007). Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Research, 67, 2081–2088.PubMedCrossRef
58.
go back to reference Takayama, H., LaRochelle, W. J., Sharp, R., Otsuka, T., Kriebel, P., Anver, M., et al. (1997). Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proceedings of the National Academy of Sciences of the United States of America, 94, 701–706.PubMedCrossRef Takayama, H., LaRochelle, W. J., Sharp, R., Otsuka, T., Kriebel, P., Anver, M., et al. (1997). Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proceedings of the National Academy of Sciences of the United States of America, 94, 701–706.PubMedCrossRef
59.
go back to reference Wang, R., Ferrell, L. D., Faouzi, S., Maher, J. J., & Bishop, J. M. (2001). Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. Journal of Cell Biology, 153, 1023–1034.PubMedCrossRef Wang, R., Ferrell, L. D., Faouzi, S., Maher, J. J., & Bishop, J. M. (2001). Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. Journal of Cell Biology, 153, 1023–1034.PubMedCrossRef
60.
go back to reference Schmidt, L., Junker, K., Nakaigawa, N., Kinjerski, T., Weirich, G., Miller, M., et al. (1999). Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene, 18, 2343–2350.PubMedCrossRef Schmidt, L., Junker, K., Nakaigawa, N., Kinjerski, T., Weirich, G., Miller, M., et al. (1999). Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene, 18, 2343–2350.PubMedCrossRef
61.
go back to reference Ferracini, R., Di Renzo, M. F., Scotlandi, K., Baldini, N., Olivero, M., Lollini, P., et al. (1995). The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene, 10, 739–749.PubMed Ferracini, R., Di Renzo, M. F., Scotlandi, K., Baldini, N., Olivero, M., Lollini, P., et al. (1995). The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene, 10, 739–749.PubMed
62.
go back to reference Ferracini, R., Olivero, M., Di Renzo, M. F., Martano, M., De, G. C., Nanni, P., et al. (1996). Retrogenic expression of the MET proto-oncogene correlates with the invasive phenotype of human rhabdomyosarcomas. Oncogene, 12, 1697–1705.PubMed Ferracini, R., Olivero, M., Di Renzo, M. F., Martano, M., De, G. C., Nanni, P., et al. (1996). Retrogenic expression of the MET proto-oncogene correlates with the invasive phenotype of human rhabdomyosarcomas. Oncogene, 12, 1697–1705.PubMed
63.
go back to reference Tuck, A. B., Park, M., Sterns, E. E., Boag, A., & Elliott, B. E. (1996). Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma. American Journal of Pathology, 148, 225–232.PubMed Tuck, A. B., Park, M., Sterns, E. E., Boag, A., & Elliott, B. E. (1996). Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma. American Journal of Pathology, 148, 225–232.PubMed
64.
go back to reference Koochekpour, S., Jeffers, M., Rulong, S., Taylor, G., Klineberg, E., Hudson, E. A., et al. (1997). Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Research, 57, 5391–5398.PubMed Koochekpour, S., Jeffers, M., Rulong, S., Taylor, G., Klineberg, E., Hudson, E. A., et al. (1997). Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Research, 57, 5391–5398.PubMed
65.
go back to reference Kijima, Y., Hokita, S., Yoshinaka, H., Itoh, T., Koriyama, C., Eizuru, Y., et al. (2002). Amplification and overexpression of c-met gene in Epstein–Barr virus-associated gastric carcinomas. Oncology, 62, 60–65.PubMedCrossRef Kijima, Y., Hokita, S., Yoshinaka, H., Itoh, T., Koriyama, C., Eizuru, Y., et al. (2002). Amplification and overexpression of c-met gene in Epstein–Barr virus-associated gastric carcinomas. Oncology, 62, 60–65.PubMedCrossRef
66.
go back to reference Nakazawa, K., Dobashi, Y., Suzuki, S., Fujii, H., Takeda, Y., & Ooi, A. (2005). Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-Met in biliary tract cancers. Journal of Pathology, 206, 356–365.PubMedCrossRef Nakazawa, K., Dobashi, Y., Suzuki, S., Fujii, H., Takeda, Y., & Ooi, A. (2005). Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-Met in biliary tract cancers. Journal of Pathology, 206, 356–365.PubMedCrossRef
67.
go back to reference Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., et al. (2007). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science, 316, 1039–1043.PubMedCrossRef Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., et al. (2007). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science, 316, 1039–1043.PubMedCrossRef
68.
go back to reference Christensen, J. G., Burrows, J., & Salgia, R. (2005). c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Letters, 225, 1–26.PubMedCrossRef Christensen, J. G., Burrows, J., & Salgia, R. (2005). c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Letters, 225, 1–26.PubMedCrossRef
69.
go back to reference Di Renzo, M. F., Olivero, M., Martone, T., Maffe, A., Maggiora, P., Stefani, A. D., et al. (2000). Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene, 19, 1547–1555.PubMedCrossRef Di Renzo, M. F., Olivero, M., Martone, T., Maffe, A., Maggiora, P., Stefani, A. D., et al. (2000). Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene, 19, 1547–1555.PubMedCrossRef
70.
go back to reference Ivan, M., Bond, J. A., Prat, M., Comoglio, P. M., & Wynford-Thomas, D. (1997). Activated Ras and Ret oncogenes induce over-expression of c-Met (hepatocyte growth factor receptor) in human thyroid epithelial cells. Oncogene, 14, 2417–2423.PubMedCrossRef Ivan, M., Bond, J. A., Prat, M., Comoglio, P. M., & Wynford-Thomas, D. (1997). Activated Ras and Ret oncogenes induce over-expression of c-Met (hepatocyte growth factor receptor) in human thyroid epithelial cells. Oncogene, 14, 2417–2423.PubMedCrossRef
71.
go back to reference Shirasaki, F., Makhluf, H. A., LeRoy, C., Watson, D. K., & Trojanowska, M. (1999). Ets transcription factors cooperate with Sp1 to activate the human tenascin-C promoter. Oncogene, 18, 7755–7764.PubMedCrossRef Shirasaki, F., Makhluf, H. A., LeRoy, C., Watson, D. K., & Trojanowska, M. (1999). Ets transcription factors cooperate with Sp1 to activate the human tenascin-C promoter. Oncogene, 18, 7755–7764.PubMedCrossRef
72.
go back to reference Gambarotta, G., Boccaccio, C., Giordano, S., Ando, M., Stella, M. C., & Comoglio, P. M. (1996). Ets up-regulates MET transcription. Oncogene, 13, 1911–1917.PubMed Gambarotta, G., Boccaccio, C., Giordano, S., Ando, M., Stella, M. C., & Comoglio, P. M. (1996). Ets up-regulates MET transcription. Oncogene, 13, 1911–1917.PubMed
73.
go back to reference Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., & Comoglio, P. M. (2003). Hypoxia promotes invasive growth by transcriptional activation of the Met protooncogene. Cancer Cell, 3, 347–361.PubMedCrossRef Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., & Comoglio, P. M. (2003). Hypoxia promotes invasive growth by transcriptional activation of the Met protooncogene. Cancer Cell, 3, 347–361.PubMedCrossRef
74.
go back to reference Morotti, A., Mila, S., Accornero, P., Tagliabue, E., & Ponzetto, C. (2002). K252a inhibits the oncogenic properties of Met, the HGF receptor. Oncogene, 21, 4885–4893.PubMedCrossRef Morotti, A., Mila, S., Accornero, P., Tagliabue, E., & Ponzetto, C. (2002). K252a inhibits the oncogenic properties of Met, the HGF receptor. Oncogene, 21, 4885–4893.PubMedCrossRef
75.
go back to reference Berthou, S., Aebersold, D. M., Schmidt, L. S., Stroka, D., Heigl, C., Streit, B., et al. (2004). The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. Oncogene, 23, 5387–5393.PubMedCrossRef Berthou, S., Aebersold, D. M., Schmidt, L. S., Stroka, D., Heigl, C., Streit, B., et al. (2004). The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. Oncogene, 23, 5387–5393.PubMedCrossRef
76.
go back to reference Christensen, J. G., Schreck, R., Burrows, J., Kuruganti, P., Chan, E., Le, P., et al. (2003). A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Research, 63, 7345–7355.PubMed Christensen, J. G., Schreck, R., Burrows, J., Kuruganti, P., Chan, E., Le, P., et al. (2003). A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Research, 63, 7345–7355.PubMed
77.
go back to reference Smolen, G. A., Sordella, R., Muir, B., Mohapatra, G., Barmettler, A., Archibald, H., et al. (2006). Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proceedings of the National Academy of Sciences of the United States of America, 103, 2316–2321.PubMedCrossRef Smolen, G. A., Sordella, R., Muir, B., Mohapatra, G., Barmettler, A., Archibald, H., et al. (2006). Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proceedings of the National Academy of Sciences of the United States of America, 103, 2316–2321.PubMedCrossRef
78.
go back to reference Date, K., Matsumoto, K., Kuba, K., Shimura, H., Tanaka, M., & Nakamura, T. (1998). Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor. Oncogene, 17, 3045–3054.PubMedCrossRef Date, K., Matsumoto, K., Kuba, K., Shimura, H., Tanaka, M., & Nakamura, T. (1998). Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor. Oncogene, 17, 3045–3054.PubMedCrossRef
79.
go back to reference Matsumoto, K., & Nakamura, T. (2003). NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics. Cancer Science, 94, 321–327.PubMedCrossRef Matsumoto, K., & Nakamura, T. (2003). NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics. Cancer Science, 94, 321–327.PubMedCrossRef
80.
go back to reference Cao, B., Su, Y., Oskarsson, M., Zhao, P., Kort, E. J., Fisher, R. J., et al. (2001). Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proceedings of the National Academy of Sciences of the United States of America, 98, 7443–7448.PubMedCrossRef Cao, B., Su, Y., Oskarsson, M., Zhao, P., Kort, E. J., Fisher, R. J., et al. (2001). Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proceedings of the National Academy of Sciences of the United States of America, 98, 7443–7448.PubMedCrossRef
81.
go back to reference Burgess, T., Coxon, A., Meyer, S., Sun, J., Rex, K., Tsuruda, T., et al. (2006). Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Research, 66, 1721–1729.PubMedCrossRef Burgess, T., Coxon, A., Meyer, S., Sun, J., Rex, K., Tsuruda, T., et al. (2006). Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Research, 66, 1721–1729.PubMedCrossRef
82.
go back to reference Mazzone, M., Basilico, C., Cavassa, S., Pennacchietti, S., Risio, M., Naldini, L., et al. (2004). An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice. Journal of Clinical Investigation, 114, 1418–1432.PubMedCrossRef Mazzone, M., Basilico, C., Cavassa, S., Pennacchietti, S., Risio, M., Naldini, L., et al. (2004). An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice. Journal of Clinical Investigation, 114, 1418–1432.PubMedCrossRef
83.
go back to reference Michieli, P., Mazzone, M., Basilico, C., Cavassa, S., Sottile, A., Naldini, L., et al. (2004). Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell, 6, 61–73.PubMedCrossRef Michieli, P., Mazzone, M., Basilico, C., Cavassa, S., Sottile, A., Naldini, L., et al. (2004). Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell, 6, 61–73.PubMedCrossRef
84.
go back to reference Kong-Beltran, M., Stamos, J., & Wickramasinghe, D. (2004). The Sema domain of Met is necessary for receptor dimerization and activation. Cancer Cell, 6, 75–84.PubMedCrossRef Kong-Beltran, M., Stamos, J., & Wickramasinghe, D. (2004). The Sema domain of Met is necessary for receptor dimerization and activation. Cancer Cell, 6, 75–84.PubMedCrossRef
85.
go back to reference Petrelli, A., Circosta, P., Granziero, L., Mazzone, M., Pisacane, A., Fenoglio, S., et al. (2006). Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. Proceedings of the National Academy of Sciences of the United States of America, 103, 5090–5095.PubMedCrossRef Petrelli, A., Circosta, P., Granziero, L., Mazzone, M., Pisacane, A., Fenoglio, S., et al. (2006). Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. Proceedings of the National Academy of Sciences of the United States of America, 103, 5090–5095.PubMedCrossRef
86.
go back to reference Corso, S., Migliore, C., Ghiso, E., De Rosa, G., Comoglio, P. M., & Giordano, S. (2007). Silencing the MET oncogene leads to regression of experimental tumors and metastases. Oncogene (in press). DOI 10.1038/sj.onc.1210697. Corso, S., Migliore, C., Ghiso, E., De Rosa, G., Comoglio, P. M., & Giordano, S. (2007). Silencing the MET oncogene leads to regression of experimental tumors and metastases. Oncogene (in press). DOI 10.​1038/​sj.​onc.​1210697.
Metadata
Title
The Met tyrosine kinase receptor in development and cancer
Authors
Alessandra Gentile
Livio Trusolino
Paolo M. Comoglio
Publication date
01-03-2008
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 1/2008
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-007-9107-6

Other articles of this Issue 1/2008

Cancer and Metastasis Reviews 1/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine